Large GWAS Study Finds DNA Variants Linked to Risk of Developing Breast Cancer
|
By LabMedica International staff writers Posted on 13 Jan 2020 |

Image: Micrograph showing a lymph node invaded by ductal breast cancer and with extranodal extension of the tumor. The dark purple (center) shows lymphocytes (part of a normal lymph node). Surrounding the lymphocytes and extending into the surrounding fat (top of image) is the ductal breast cancer (Photo courtesy of Wikimedia Commons)
A large multinational study identified more than 350 DNA variants associated with the more than 150 regions of the genome known to be linked to the risk for developing breast cancer.
Investigators at more than 450 departments and institutions worldwide, including the University of Cambridge (United Kingdom) and the Wellcome Sanger Institute (Hinxton, United Kingdom), collaborated to compare the DNA of 110,000 breast cancer patients against that of some 90,000 healthy controls.
Previous genome-wide association studies (GWAS), which compared the DNA of patients against that of healthy controls, found around 150 regions of the genome that clearly affected breast cancer risk. The use of advanced gene mapping techniques in the current study enabled investigators to identify 352 risk variants within these regions. So far, it is not yet clear how many genes these variants target, but the investigators have identified 191 genes with reasonable confidence.
In the majority of cases, the variants affected gene expression, how active a particular gene was and how much of a particular protein it created, rather than altering the type of protein coded by the gene. Of the newly-discovered genetic variants, about a third predispose women towards developing hormone-responsive breast cancer, the type of disease found in 80% of breast cancer patients. These tumors respond to hormonal treatments such as tamoxifen. In contrast, 15% of the genetic variants predispose women to the rarer estrogen-receptor-negative type of breast cancer.
"We know from previous studies that variants across our DNA contribute towards breast cancer risk, but only rarely have scientists have been able to identify exactly which genes are involved," said first author Dr. Laura Fachal researcher in human genetics at the Wellcome Sanger Institute. "We need this information as it gives us a better clue to what is driving the disease and hence how we might treat or even prevent it."
"This incredible haul of newly-discovered breast cancer genes provides us with many more genes to work on, most of which have not been studied before," said senior author Dr. Alison Dunning, reader in molecular cancer genetics at the University of Cambridge. "It will help us build up a much more detailed picture of how breast cancer arises and develops. But the sheer number of genes now known to play a role emphasizes how complex the disease is."
The breast cancer genome-wide association study was published in the January 7, 2020, online edition of the journal Nature Genetics
Related Links:
University of Cambridge
Wellcome Sanger Institute
Investigators at more than 450 departments and institutions worldwide, including the University of Cambridge (United Kingdom) and the Wellcome Sanger Institute (Hinxton, United Kingdom), collaborated to compare the DNA of 110,000 breast cancer patients against that of some 90,000 healthy controls.
Previous genome-wide association studies (GWAS), which compared the DNA of patients against that of healthy controls, found around 150 regions of the genome that clearly affected breast cancer risk. The use of advanced gene mapping techniques in the current study enabled investigators to identify 352 risk variants within these regions. So far, it is not yet clear how many genes these variants target, but the investigators have identified 191 genes with reasonable confidence.
In the majority of cases, the variants affected gene expression, how active a particular gene was and how much of a particular protein it created, rather than altering the type of protein coded by the gene. Of the newly-discovered genetic variants, about a third predispose women towards developing hormone-responsive breast cancer, the type of disease found in 80% of breast cancer patients. These tumors respond to hormonal treatments such as tamoxifen. In contrast, 15% of the genetic variants predispose women to the rarer estrogen-receptor-negative type of breast cancer.
"We know from previous studies that variants across our DNA contribute towards breast cancer risk, but only rarely have scientists have been able to identify exactly which genes are involved," said first author Dr. Laura Fachal researcher in human genetics at the Wellcome Sanger Institute. "We need this information as it gives us a better clue to what is driving the disease and hence how we might treat or even prevent it."
"This incredible haul of newly-discovered breast cancer genes provides us with many more genes to work on, most of which have not been studied before," said senior author Dr. Alison Dunning, reader in molecular cancer genetics at the University of Cambridge. "It will help us build up a much more detailed picture of how breast cancer arises and develops. But the sheer number of genes now known to play a role emphasizes how complex the disease is."
The breast cancer genome-wide association study was published in the January 7, 2020, online edition of the journal Nature Genetics
Related Links:
University of Cambridge
Wellcome Sanger Institute
Latest Molecular Diagnostics News
- Diagnostic Device Predicts Treatment Response for Brain Tumors Via Blood Test
- Blood Test Detects Early-Stage Cancers by Measuring Epigenetic Instability
- Two-in-One DNA Analysis Improves Diagnostic Accuracy While Saving Time and Costs
- “Lab-On-A-Disc” Device Paves Way for More Automated Liquid Biopsies
- New Tool Maps Chromosome Shifts in Cancer Cells to Predict Tumor Evolution
- Blood Test Identifies Inflammatory Breast Cancer Patients at Increased Risk of Brain Metastasis
- Newly-Identified Parkinson’s Biomarkers to Enable Early Diagnosis Via Blood Tests
- New Blood Test Could Detect Pancreatic Cancer at More Treatable Stage
- Liquid Biopsy Could Replace Surgical Biopsy for Diagnosing Primary Central Nervous Lymphoma
- New Tool Reveals Hidden Metabolic Weakness in Blood Cancers
- World's First Blood Test Distinguishes Between Benign and Cancerous Lung Nodules
- Rapid Test Uses Mobile Phone to Identify Severe Imported Malaria Within Minutes
- Gut Microbiome Signatures Predict Long-Term Outcomes in Acute Pancreatitis
- Blood Test Promises Faster Answers for Deadly Fungal Infections
- Blood Test Could Detect Infection Exposure History
- Urine-Based MRD Test Tracks Response to Bladder Cancer Surgery
Channels
Clinical Chemistry
view channel
New PSA-Based Prognostic Model Improves Prostate Cancer Risk Assessment
Prostate cancer is the second-leading cause of cancer death among American men, and about one in eight will be diagnosed in their lifetime. Screening relies on blood levels of prostate-specific antigen... Read more
Extracellular Vesicles Linked to Heart Failure Risk in CKD Patients
Chronic kidney disease (CKD) affects more than 1 in 7 Americans and is strongly associated with cardiovascular complications, which account for more than half of deaths among people with CKD.... Read moreHematology
view channel
New Guidelines Aim to Improve AL Amyloidosis Diagnosis
Light chain (AL) amyloidosis is a rare, life-threatening bone marrow disorder in which abnormal amyloid proteins accumulate in organs. Approximately 3,260 people in the United States are diagnosed... Read more
Fast and Easy Test Could Revolutionize Blood Transfusions
Blood transfusions are a cornerstone of modern medicine, yet red blood cells can deteriorate quietly while sitting in cold storage for weeks. Although blood units have a fixed expiration date, cells from... Read more
Automated Hemostasis System Helps Labs of All Sizes Optimize Workflow
High-volume hemostasis sections must sustain rapid turnaround while managing reruns and reflex testing. Manual tube handling and preanalytical checks can strain staff time and increase opportunities for error.... Read more
High-Sensitivity Blood Test Improves Assessment of Clotting Risk in Heart Disease Patients
Blood clotting is essential for preventing bleeding, but even small imbalances can lead to serious conditions such as thrombosis or dangerous hemorrhage. In cardiovascular disease, clinicians often struggle... Read moreImmunology
view channelBlood Test Identifies Lung Cancer Patients Who Can Benefit from Immunotherapy Drug
Small cell lung cancer (SCLC) is an aggressive disease with limited treatment options, and even newly approved immunotherapies do not benefit all patients. While immunotherapy can extend survival for some,... Read more
Whole-Genome Sequencing Approach Identifies Cancer Patients Benefitting From PARP-Inhibitor Treatment
Targeted cancer therapies such as PARP inhibitors can be highly effective, but only for patients whose tumors carry specific DNA repair defects. Identifying these patients accurately remains challenging,... Read more
Ultrasensitive Liquid Biopsy Demonstrates Efficacy in Predicting Immunotherapy Response
Immunotherapy has transformed cancer treatment, but only a small proportion of patients experience lasting benefit, with response rates often remaining between 10% and 20%. Clinicians currently lack reliable... Read moreMicrobiology
view channel
Comprehensive Review Identifies Gut Microbiome Signatures Associated With Alzheimer’s Disease
Alzheimer’s disease affects approximately 6.7 million people in the United States and nearly 50 million worldwide, yet early cognitive decline remains difficult to characterize. Increasing evidence suggests... Read moreAI-Powered Platform Enables Rapid Detection of Drug-Resistant C. Auris Pathogens
Infections caused by the pathogenic yeast Candida auris pose a significant threat to hospitalized patients, particularly those with weakened immune systems or those who have invasive medical devices.... Read morePathology
view channel
Engineered Yeast Cells Enable Rapid Testing of Cancer Immunotherapy
Developing new cancer immunotherapies is a slow, costly, and high-risk process, particularly for CAR T cell treatments that must precisely recognize cancer-specific antigens. Small differences in tumor... Read more
First-Of-Its-Kind Test Identifies Autism Risk at Birth
Autism spectrum disorder is treatable, and extensive research shows that early intervention can significantly improve cognitive, social, and behavioral outcomes. Yet in the United States, the average age... Read moreTechnology
view channel
Robotic Technology Unveiled for Automated Diagnostic Blood Draws
Routine diagnostic blood collection is a high‑volume task that can strain staffing and introduce human‑dependent variability, with downstream implications for sample quality and patient experience.... Read more
ADLM Launches First-of-Its-Kind Data Science Program for Laboratory Medicine Professionals
Clinical laboratories generate billions of test results each year, creating a treasure trove of data with the potential to support more personalized testing, improve operational efficiency, and enhance patient care.... Read moreAptamer Biosensor Technology to Transform Virus Detection
Rapid and reliable virus detection is essential for controlling outbreaks, from seasonal influenza to global pandemics such as COVID-19. Conventional diagnostic methods, including cell culture, antigen... Read more
AI Models Could Predict Pre-Eclampsia and Anemia Earlier Using Routine Blood Tests
Pre-eclampsia and anemia are major contributors to maternal and child mortality worldwide, together accounting for more than half a million deaths each year and leaving millions with long-term health complications.... Read moreIndustry
view channelNew Collaboration Brings Automated Mass Spectrometry to Routine Laboratory Testing
Mass spectrometry is a powerful analytical technique that identifies and quantifies molecules based on their mass and electrical charge. Its high selectivity, sensitivity, and accuracy make it indispensable... Read more
AI-Powered Cervical Cancer Test Set for Major Rollout in Latin America
Noul Co., a Korean company specializing in AI-based blood and cancer diagnostics, announced it will supply its intelligence (AI)-based miLab CER cervical cancer diagnostic solution to Mexico under a multi‑year... Read more
Diasorin and Fisher Scientific Enter into US Distribution Agreement for Molecular POC Platform
Diasorin (Saluggia, Italy) has entered into an exclusive distribution agreement with Fisher Scientific, part of Thermo Fisher Scientific (Waltham, MA, USA), for the LIAISON NES molecular point-of-care... Read more







